Baqsimi Nasal Glucagon Shortage

21 January 2025

Notice of Glucagon Nasal Powder (Baqsimi®) shortage and recommended care adjustments

Amphastar is reporting a shortage of Baqsimi® (Glucagon Nasal Powder). This shortage has been caused by a change in the product packaging site and is estimated to end by February 27, 2025.

As part of CSEM’s ongoing efforts, we are working with Diabetes Canada, Health Canada, Amphastar as well as the Provincial and Territorial Drug Shortages Task Team (PT DSTT) to monitor and manage the situation. We will continue to provide updates as information becomes available. Injectable glucagon remains available.

CSEM recommends that endocrinologists discuss the following strategies with people living with diabetes and their care providers:

  • Verify access and expiration dates: people living with diabetes who rely on Baqsimi® are encouraged to check the expiration date of their Glucagon nasal powder and ensure it is readily accessible in case of an emergency. If the product is expired, it is recommended to consult a pharmacist to discuss whether expired medication can still be used during the shortage.
  • Focus on hypoglycemia prevention: preventing hypoglycemia remains critical, particularly during this shortage of Baqsimi®. People with diabetes and their caregivers should be vigilant in managing blood sugar levels to avoid severe lows that require glucagon intervention.
  • Inform caregivers and family members: caregivers, family members, and others who may need to administer Baqsimi® in the event of severe hypoglycemia should be informed about the current shortage and ensured they understand how to access the medication, if available.
  • Use alternative measures in case of severe hypoglycemia: if Baqsimi® or any other glucagon treatment is not available, alternative measures should be explored:
    • If the person is conscious, attempt to administer rapidly acting carbohydrates orally.
    • If the individual is unconscious or unable to consume oral sugars, call for emergency medical assistance immediately.

CSEM urges endocrinologists and health care providers to discuss the above strategies with those at risk of severe hypoglycemia to ensure they are prepared for any emergency situation. We caution people against over-purchasing Baqsimi®, as the shortage is set to end by February 27, 2025, and stockpiling could trigger unnecessary shortages in the interim.

For further details, please visit Drug Shortages Canada or contact Amphastar’s client care line 1-800-423-4136 or This email address is being protected from spambots. You need JavaScript enabled to view it..

We will monitor the supply of Baqsimi® and provide any new information as it becomes available. CSEM will continue to advocate for access to medications for Canadian patients. If you would like to help, please join our This email address is being protected from spambots. You need JavaScript enabled to view it..